Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Fig. 2

Non-parametric multidimensional similarity analysis (NDMS) based on Bray–Curtis dissimilarity for microbiome compositions of RBX2660 and responder microbiome compositions before treatment (BL) and 1, 4, and 8 weeks after last received RBX2660 treatment. A Treatment responders. B Treatment non-responders

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us